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ABSTRACT
Cancer remains a major medical problem accounting for over 500,000 deaths in the
US annually. A common feature of most human tumors is their ability to induce the
proliferation of new blood vessels, i.e. angiogenesis. Considerable evidence now exists
which demonstrates that these tumor vessels are associated with a distinct range of
morphological and physiological properties which are not present in normal tissue
vasculature. Several studies now document that in a wide variety of tumor models, average
tumor vessels have diameters two times those of normal tissue vessels. NMR techniques
based on magnetic susceptibility mechanisms are sensitive to varying sizes of blood
vessels. By using gradient echo (GE) and spin echo (SE) pulse sequences and different
concentrations of an exogenous contrast agent, it is possible to determine the signal
contribution from small versus large vessels by examining the change in T2 and T2* rates
(AR2 and AR2*), i.e. the ratio of AR2* to AR2 increases with vessel size. This ratio
provides an index for the average size of vessels within a voxel. The central goal of this
research was to utilize such a tool in order to obtain a regional picture of the tumor vascular
bed.
Rats, inoculated with C6 glial cells, underwent an MR imaging series nineteeti days
after implantation, which comprised conventional SE and GE images prior to and foll6wing
serial injections of an equilibrium iron oxide contrast agent (MION). Regions within the
tumor and in the contralateral normal gray matter were identified. The change in the T2 rate
and T2* rate (AR2 and AR2*) were calculated for each region. Since susceptibility
contrast mechanisms designed to study the distribution of vessel sizes rely entirely on the
compartmentalization of the contrast agent within the vasculature, the first set of
experiments was designed to demonstrate the stability of MION to remain within the
vasculature, despite the disruption in the blood brain barrier. The second experiments
measured AR2 and AR2* as a function of contrast agent concentration and TE. The MR
measurements were compared with predicted values of AR2 and AR2* made from
histological assessment of vessel sizes and theoretical Monte Carlo simulation results.
The steady state measurements of AR2 and AR2* in the first experiments
demonstrated that once the maximum contrast agent concentration had been reached, the
values of AR2 and AR2* remained stable over 90 minutes, suggesting that MION remains
within the vasculature. In the second experiments, significant differences were observed
between the tumor and contralateral deep gray matter. Specifically, the ratio of R2*/ R2
was greater in the tumor than the normal brain, by a factor of 1.9 ± 0.2. From histologic
sections and numerical simulations, the corresponding ratio was predicted to be 1.9 ± 0.1.
These ratios are suggestive of a greater relative density of large vs small vessels. Maps of
the ratio AR2*/AR2 were also produced on a pixel by pixel basis. Regions of high
intensity on these maps (indicating a higher ratio of AR2*/AR2) corresponded well with the
location of the tumor as determined using conventional images.
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Chapter I
INTRODUCTION
Cancer. It is the second leading cause of death in the United States, exceeded only
by heart disease. Although some cancers such as cervical, colon, rectal and testicular have
seen a decline in mortality over the past twenty years, there has been an overall 7% increase
in death rate per 100,000 population. This year alone, over 560,000 people will die of
cancer, and over 1,350,000 new invasive cancers will be diagnosed - not including
carcinoma in situ or basal and squamous cell carcinoma. In 1990, there were 20,500 new
cases of primary brain tumors and over 20,700 new cases of metastatic brain tumors.
Seventy-five percent of these patients will die within a year of diagnosis. Primary
malignant brain tumors are the second most common cause of cancer death in people under
34 years of age. Despite concentrated efforts to improve both radiation therapy and
chemotherapy, the five year survival rate for patients suffering from brain tumors has only
improved by 11% in the past thirty years (18% in 1960 to 29% in 1990) (1). This type of
cancer remains one of the deadliest. New diagnostic and therapeutic strategies are required
to increase survival in these patients.
The cause of primary brain tumor is unknown, as is the case for most caticers,
despite advances in molecular biology. Environmental agents, familial tendencies and viral
causes are all under investigation. Brain tumors originate from various cells: neuromas are
tumors of the nerves themselves; astrocytomas arise from astrocyte cells; lymphomas are
cancers of the immune system; ependyomas arise from ependymal cells which form the
lining of the ventricles and central canal of the spinal cord; hemangioblastomas originate
from blood vessels; meningiomas arise from the meninges; pituitary adenomas are slow
growing tumors of the pituitary gland. Some of these tumors are usually benign
(neuromas, hemangioblastomas, meningiomas and pituitary adenomas) while most gliomas
(tumors arising from the glial or supportive tissue of the brain) can present at various stages
of. growth and aggressiveness, from low grade to high grade. Often, tumors contain
several grades of cells. The highest or most malignant grade of cell found determines the
grade of the tumors, even if most of the tumor is a lower grade. Tumor diagnosis by name
and by grade is very important for both treatment and prognosis (1).
Brain cancer can be very difficult to diagnose because of the protective nature of the
skull. A physician is unable to see or feel a brain tumor during a routine examination.
Non-invasive imaging studies such as those performed using CT and MRI can obtain a
picture of the brain to provide clues which may suggest a particular type of tumor. Only a
sample of tumor obtained via biopsy and examined under a microscope can provide an
exact diagnosis. However, because of the inherent heterogeneity of tumors, biopsies are
subject to potential sampling errors because routinely only one or two small portions of the
tumor are assayed and repeat biopsy is not feasible. It is possible that in the future, tumor
markers may help identify the presence of a tumor. Relatively non-invasive techniques
such a blood tests could screen for the presence of various tumor markers to determine the
presence or regrowth of certain tumors. Unfortunately, these markers do not indicate the
location or extent of a tumor, only its presence. Many tests would have to be carried out to
determine the exact diagnosis of the tumor, since these markers are cell specific.
Imaging techniques, including Computed Tomography (CT), Magnetic Resonance
Imaging (MRI) and Positron Emission Tomography (PET) have become very useful in the
diagnosis and follow-up of cancers. Brain tumors often cause tmuch of their damage due
to their size and hindrance of vital sections of the brain. This mass effect can usually be
seen on anatomical scans as deviations from normal anatomy. However, a simple
anatomical image does not provide information about grade or aggressiveness of a tumor.
Radiation necrosis, which is caused by the radiation treatments given patients, may also
have similar mass effects and thus look identical to recurring tumor. Tumors are known
however to differ in function from normal tissue and from necrosis. For example, high
grade lesions because of their aggressive nature and uncontrolled growth require a large
amount of nutrients. In the brain, that nutrient is primarily glucose. By injecting glucose
which has been labeled with radioactive fluorine (FDG), the increased intake of glucose by
the tumor can be monitored via PET as shown in figure 1-1. Low grade tumors have a
slower metabolism, requiring less energy. A low grade tumor would therefore not appear
as an FDG hot spot. Although this is a significant improvement to simple anatomical
images, PET suffers from low resolution. It may not be able to resolve very small focal
increases in glucose uptake, which would be indicative of a local region of high grade
tumor.
Post Gd FDG
Figure 1-1: High grade tumor. The image on the left is a post-Gd image
enhancing the location of the lesion due to the disruption of the Blood Brain Barrier
(BBB). The PET FDG image on the right shows the lesion with high glucose
uptake, characteristic of a high grade tumor.
Another common feature of solid tumors is their increased vasculature. Tumors are
in fact capable of inducing the proliferation of new blood vessels - a process known as
angiogenesis. The microvascular system in the adult remains quiescent without capillary
growth for prolonged periods (2). However, within a short time, it appears to be capable
of responding to both physiologic and pathophysiologic demands. The term angiogenesis
was coined in 1935 by Hertig (3) to describe the neovascularization in the developing
placenta. It is also found in the development of the corpus luteum following ovulation and
in the granulation tissue of wound healing. Angiogenesis also plays a major role in many
diseases (4) such as diabetic retinopathy (5), atherosclerosis (6), rheumatoid arthritis (7)
and most importantly cancer (8). For over 100 years, solid tumors have been known to be
associated with an increased vascular supply, but detailed studies of tumor angiogenesis
only began about 50 years ago. In 1939, Ide et. al. (9) surmised that "it is probable that
tumors may be elaborating a vessel growth stimulating substance". Algire et. al. (10) then
showed that tumor implants began to grow in size only after the initial vascularization
occurred, implying that the capacity of tumors to stimulate perpetual growth of new
capillaries from the host may be the fundamental difference between the malignant cell and
the normal cell from which it arose. In 1966, Folkman et. al. (11) reported that when
tumors were grown in isolated perfused organs where blood vessels do not proliferate,
they reach a maximum size of only 1-2 mm 3. However, on transplantation to mice these
tumors induce vascularization and expand rapidly to 1-2 cm 3. Based on the data cited
above, Folkman (12) proposed the hypothesis that "tumor growth is angiogenesis-
dependent". This hypothesis can be stated as follows: "In its simplest terms, once tumor
take has occurred, every increase in tumor cell population must be preceded by an increase
in new capillaries converging on the tumor" (4).
Over the last 20 years, many lines of evidence have accumulated supporting
Folkman's hypothesis (8, 13) including the discovery of various angiogenic factors which
are released by tumor cells themselves(14-17). While much of this work has been
performed on tumor and cell lines from outside the brain, it has also been demonstrated that
glioma cells have high levels of expression of multiple immunoreactive forms of angiogenic
growth factors (18, 19). In fact, of the following list of histologic characteristics of
glioblastomas: high cell density, cellular pleomorphism, mitoses, necroses with palisading
cells and prominent vascularization with endothelial cell proliferation (20), Burger et. al.
(21) noted that in a study of 1440 malignant astrocytic gliomas, only vascular proliferation
differentiated anaplastic astrocytomas into short and long-term survival categories. This
increased vascularization therefore offers another opportunity by which to characterize
lesions in the central nervous system (CNS) by using imaging techniques which highlight
the vasculature.
PET can measure Cerebral Blood Volume (CBV) by using carbon monoxide
labeled 150 which remains in the vasculature by binding with the hemoglobin present in red
blood cells (22). The increased vasculature present in tumors is located within the
microcirculation, i.e., within vessels on the micron scale. In normal brain, the
microvascular system makes up only 4% of tissue. In a low resolution scan such as PET,
where a single voxel is on the order of a cm 2, signal from the microcirculation is lost. Only
voxels which consist of pure blood vessels will register as high intensity. Therefore, PET
CBV images are mostly representative of large arteries and veins.
Magnetic resonance imaging techniques have been developed which can map both
normal and abnormal brain microvascular hemodynamics, including CBV. These
techniques, based on magnetic susceptibility contrast mechanisms are more sensitive to the
microvasculature (see chapter two) than are the PET techniques and can therefore provide
better information about the increased microcirculation of brain neoplasms. Briefly, a
paramagnetic contrast agent is injected into the patient's vein. As the agent circulates
through the brain, it will induce inhomogeneities in the local magnetic field in the tissues
surrounding the vasculature. With high speed imaging techniques such as echo planar
imaging (EPI), the dynamic first pass effects of the contrast agent can be recorded before
the agent is washed out of the vasculature. Areas of high microvascular blood volume will
cause increased changes in the surrounding tissue, thus appearing as bright regions in CBV
maps, as shown in figure 1-2. This figure is representative of a high grade glioma
associated with an increase blood volume. Evaluation of patients with primary brain
tumors using high speed susceptibility contrast techniques can have significant impact on
the diagnosis, prognosis and/or management of patients. Studies have been conducted
which show a positive correlation between relative CBV and tumor grade (23, 24). These
studies are used to aid in initial diagnosis, provide important information on patient
prognosis, guide surgical interventions and biopsies and provide early surveillance for
evidence of malignant dedifferentiation and tumor recurrence post treatment.
T2 CBV map
Figure 1-2: High grade glioma. Image on the image is a T2 weighted image.
Image on the right is the rCBV map showing a high intensity region
corresponding to the increased vasculature present in high grade tumors
Along with increased vasculature, it is well known that tumor vessels are associated
with a distinct range of both morphological and physiological properties which are not
present in normal tissue vasculature. Qualitatively, tumor vessels are disorderly and
dominated by large, dilated and tortuous vascular structures with increased vessel spacing.
Deane and Lantos (25) studied the various phases of vascularization of rat glioma and
discovered that in the late phase of growth, microvessels with diameters on the order of 40
pm could be found in the intermediate zone of the tumor, i.e. the zone between the necrotic
core and the proliferating edge. These vessels also varied in shape and size. Using
scanning electron microscopy on tumor vascular casts, Zama et. al. (26) were able to
assess the three dimensional growth patterns of rat gliomas. They found large budding
vessels which attained diameters of 250 pm. These buds, although filled with blood, did
not have normal blood flow characteristics. Dewhirst et. al. compared the newly forming
blood vessels in tumors with those of granulation tissue found in wound healing (27).
They discovered that on average, tumor vessels had diameters two to three times greater
than those of normal proliferating vessels.
The mechanism of image contrast associated with magnetic susceptibility contrast
techniques is dominated by the compartmentalization and delivery of the contrast agent.
Both theoretical and empirical data (28-33) have suggested that microscopic tissue
properties such as blood vessel size and density affect susceptibility-sensitive imaging
techniques. These effects will be described in greater detail in chapter two. Briefly, the
compartmentalization of paramagnetic contrast agents within the vasculature induces long-
range magnetic field perturbations which shorten the T2 and T2* of the tissue. The range
at which these effects are measurable depends on the size of the blood vessel containing the
contrast agent. The enhancement of the transverse magnetization relaxation rate, known as
relaxivity, can be expressed as follows:
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where T2 pre and T2post are the tissue T2 in the absence and presence, respectively, of field
perturbations (similarly for T2*), So and Spost are the signal intensities in the absence and
presence of field perturbations, respectively.
Both AR2 and AR2* have been shown to vary with vessel size (31, 32), as shown
in figure 1-3. Shown here for a concentration of contrast agent comparable to physiologic
injections of Gd-DTPA, AR2 and AR2 first increase as a function of vessel size. At larger
vessel radii (> 8 pm), AR2 decreases to zero whereas AR2* maintains a constant value,
independent of vessel size. AR2 peaks for vessels with radii on the order of 3-4 pm,
corresponding to normal microvasculature. It is important to note the ratio of AR2* to AR2
increases as the size of the vessels increases. This ratio could thus be used as an index of
the average vessel size present within a voxel.
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Figure 1-3: AR2 and AR2* as a function of vessel radius
Based on this theory and the fact that tumor vessels can have diameters two to three
times greater than normal tissue capillaries (27), MRI could therefore provide another
marker for tumor growth, by obtaining a regional picture of tumor vascular morphology.
Specific Aims
To examine whether tumor vessels have different morphologic characteristics than
normal vessels, this research will study an established rat glioma model - the C6 model.
AR2 and AR2* measurements will be made as a function of contrast agent concentration
and as a function of echo time. An equilibrium iron oxide agent known as MION
(Monocrystalline Iron Oxide Nanoparticle) will be used as the contrast agent.
Aside from these morphologic properties unique to tumor vessels, tumor
vasculature is also characterized by a range of physiologic properties not shared by normal
tissue capillaries. Specifically, tumor capillaries are known to be hyperpermeable (14). In
the brain, a barrier known as the blood-brain-barrier (BBB) controls the transport of
various chemicals, hormones and nutrients from the vasculature into the brain parenchyma.
)
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Blood vessels in brain tumors are known to have a disruption of the BBB, making them
more permeable to agents injected within the vasculature. Additionally, factors released by
the tumor cells themselves such as vascular endothelial growth factor, also known as
vascular permeability factor (VEGF/VPF) increase the permeability of capillaries to solutes.
These combining factors make brain tumor capillaries hyperpermeable.
Susceptibility contrast mechanisms rely entirely on the compartmentalization of the
contrast agent within the vasculature. If the agent were to leak out of the vessels faster than
its first passage through the microcirculation, no signal changes would be recorded. It is
therefore important to determine whether the contrast agent used to measure the relaxivity
(AR2 and AR2*) remains intravascularly. Although MION has a diameter of
approximately 40 nm (34) which is too large to cross the blood brain barrier, it may be
possible that with a disruption of the BBB, this agent will leak out of the vessels. The first
set of experiments shown will examine the measurements of AR2 and AR2* as a function
of time, establishing the stability of MION to remain within the vasculature.
The second set of experiments will examine the ratio of AR2* to AR2 as a function
of contrast agent concentration and echo time. Based on the theory, this ratio should be
larger in the region of the tumor where larger microvessels should dominate the
microcirculation system. It is also possible to create maps of AR2*/AR2 on a pixel by
pixel basis in order to examine the regional picture of the microvascular bed.
Finally, in order to demonstrate the validity of this model, histologic assessment of
vessel size will be performed in both the tumor and the contralateral grey matter of the
brain. A direct comparison of the histologic data and the MR data will be described and
results shown.
Outline of thesis
Chapter two will provide the theoretical background upon which this theory is
based. The basic principles of NMR will be briefly outlined, followed by a presentation of
studies which have described the effects of vessel size on relaxivity. Chapter three will
present experimental methods and materials as well as the analysis methods used in these
experiments. The results from the experiments and the data analysis will be presented in
chapter four. Finally, a discussion of the material presented will be offered in chapter five.
Chapter II
THEORY OF MAGNETIC
SUSCEPTIBILITY CONTRAST
The discovery of NMR dates back some fifty years to the work of Bloch (35) and
Purcell (36) in 1946. The impact of their work was immediate with applications in
physics, chemistry, biology and eventually in medicine. The advent of Nuclear Magnetic
Resonance Imaging (MRI) took somewhat longer to develop. In 1973, Lauterbur (37)
was the first to publish an image of two tubes of water, which was obtained via a series of
back-projections using field gradients. The first human image of a live finger was reported
in 1976 (38). Since then, NMR images have improved in quality, resolution, contrast to
noise and tissue discrimination.
MRI presents several distinct advantages over other imaging modalities. First and
foremost, it does not use ionizing radiation like x-rays, CT, PET or SPECT. In contrast
with ultrasound, the energy used in MRI is capable of penetrating bony structures without
attenuation. The relaxation parameters inherent to MRI are able to provide not only
excellent anatomical information, but also physiologic information not previously seen with
other modalities (i.e. multiple sclerosis plaques). Finally, unlike CT, MRI can visualize an
object in axial, coronal or sagittal slices, or slices of arbitrary orientation (39).
2.1 THE NMR SIGNAL
Nuclear magnetic resonance can be performed on any element which possesses a
magnetic moment and spin. The nuclei which possess this property have an odd number of
either protons or neutrons. Such nuclei are characterized by an inherent property known as
the gyromagnetic ratio. For example, hydrogen, with only one proton, has a gyromagnetic
ratio of 42.58 MHz/T. Although any such nuclei could be used for imaging the human
body, hydrogen, with a spin of 1/2, is most often used because of its high natural
abundance as well as its high gyromagnetic ratio. As a consequence, standard clinical
images are often referred to as proton images.
Because of the magnetic moment inherent to protons, these nuclei behave somewhat
like a tiny bar magnet. Much like the compass of a needle which aligns itself with a
magnetic field, protons will act in a similar manner when exposed to an external magnetic
field. Unlike the needle however, quantum mechanics dictate that the longitudinal
component of the nuclear magnetization will take on one of two states: parallel or anti-
parallel to the external magnetic field. These two alignments correspond, respectively to
lower and higher energy states. Within this applied magnetic field, there is always an small
excess of protons, also referred to as spins, which fall into the lower energy state. As
such, a net magnetization (M) will exist in the direction of the applied field (figure 2-1).
By convention, the external magnetic field is applied along the z-direction. The net
magnetization is proportional to the strength of the external field (Bo). The larger the
applied magnetic field, the larger the magnitude of M. This will increase the MRI signal,
which explains why the MRI scanners are heading towards higher and higher field
strengths.
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Figure 2-1: Because more spins align with the external magnetic field, a net
magnetization will exist in the sample
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Although the protons are said to be aligned with or against Bo, in reality, they are
precessing around the main magnetic field at a frequency known as the Larmor frequency:
o = yB (2.1)
where co = Larmor frequency (MHz), 7 = gyromagnetic ratio (MHz/T) and B0 = applied
magnetic field strength (T). The individual magnetizations of the protons therefore have
projections along the z-axis which form the net magnetization M but the projections on the
x-y plane sum to zero.
If a second, smaller magnetic field (B1) is applied along either the x or y direction,
i.e., perpendicular to M, the net magnetization will rotate away from the z-axis at the
Larmor frequency (figure 2-2). However, as soon as M is tipped slightly from the z-axis,
Bo will tend to bring it back because of its relatively greater strength. If B also precesses
at the Larmor frequency, then it will remain perpendicular to M. This will cause the net
magnetization to continue to move away from the z-axis. Its final position with respect to
the z-axis is dependent upon the duration and strength of B1 and its final angle with respect
to the z-axis is known as the flip angle. Since this applied field is rotating at a frequency in
the MHz range which is in the radiofrequency (RF) range, it is referred to as the RF pulse.
For example, if the net magnetization lands in the x-y plane, also known as the transverse
plane, the RF pulse is a 90" RF pulse. To simplify the motion, it is easiest to view this
process in a rotating frame of reference. If the coordinate system rotates at the Larmor
frequency, then the 90" RF pulse is seen to produce a simple tilt of the magnetization into
the transverse plane (figure 2-3).
Once the net magnetization is in the transverse plane and the RF pulse is removed,
M will precess about the z-axis. According to Faraday's law, a time varying magnetic field
will induce a voltage in an antenna surrounding the sample. This voltage which is
proportional to the magnitude of the magnetization is the MRI signal (figure 2-4).
Mz
Figure 2-2: Effect of a 900 pulse on the net magnetization M is
the transverse plane in a spiraling motion.
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Figure 2-3: Effect of a 90' RF pulse as seen in the rotating frame of
reference
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Figure 2-4: The precessing transverse magnetization will produce a voltage in a
properly designed antenna surrounding the sample. The voltage is proportional to the
amplitude of the net magnetization.
2.2 RELAXATION
There are several tissue-related factors which affect the strength of the NMR signal.
The most important of these is known as relaxation and refer to the process by which spins
return to their equilibrium state following the perturbing effects of the RF pulse. There are
two mechanisms by which this may occur: 1) T1 relaxation also known as spin-lattice
relaxation and 2) T2 relaxation, also known as spin-spin relaxation. Each of these
parameters is a characteristic of each tissue or substance. They can however be altered by
changing the temperature of the sample and/or the external magnetic field or by adding
contrast agents to the sample.
2.2.1 T1 Relaxation
T 1 relaxation is most easily understood in terms of M. If M is tipped into the
transverse plane by a 90o RF pulse, there will be no component remaining along the z-axis.
------
t
The T1 relaxation time is an exponential time constant that relates to the period required for
the longitudinal, or z, component to recover from zero to its maximal value (figure 2-5).
Although the NMR signal originates from the transverse magnetization, there must exist a
longitudinal magnetization in the z-axis in order to create the transverse magnetization.
Therefore, if any experiment is to be repeated (as most NMR experiments are), the
repetition time (TR) must allow for sufficient longitudinal magnetization to recover. TR is
thus dependent upon the T1 of the sample.
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Figure 2-5: After the 900 pulse, the longitunal magnetization will return to its initial
value in an exponential manner with a time constant of T1.
A TI-weighted image takes advantage of the varying T 1 values present within a
sample. As a simple example, consider a sample contains two substances, one with a short
T 1 and the other with a long Ti. If the repetition time is chosen such that the substance
with the short T has recovered most of its longitudinal magnetization while the substance
with the long TI has only recovered a small amount (figure 2-6), then the signal following
the 900 RF pulse will be weighted by the amount of magnetization which has recovered.
This difference provides contrast between the two substances.
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Figure 2-6: By choosing the repetition time appropriately, differences in T 1 will
provide image contrast.
2.2.2 T2 Relaxation
T2 can be most easily understood if the net transverse magnetization is seen as the
sum of individual magnetic moments. Once the RF pulse is removed, each spin will
precess about the z-axis at or near the Larmor frequency. Local magnetic field
inhomogeneities cause some nuclei to experience a slightly stronger magnetic field and
others to experience a weaker field. Since the precessional frequency is direction
proportional to the magnetic field experienced by the protons, those in the stronger field
will precess faster while those in the weaker field will precess more slowly. This loss of
phase coherence between the protons is known as dephasing. It will result in a loss of net
transverse magnetization, as shown in figure 2-7. T2 is the exponential time constant
which relates to the loss of this transverse magnetization. Since the transverse
magnetization is responsible for the NMR signal, its reduction will cause signal loss (figure
2-7).
The local magnetic field inhomogeneities noted previously are produced by two
factors: 1) microscopic effects due to magnetic interactions with neighboring molecules or
2) macroscopic effects due to inhomogeneities of the external magnetic field B0 .
Dephasing which is due to molecular interactions alone is called T2 while dephasing due to
both processes is called T2*. With a perfect magnet, T2 would be identical to T2. In
reality, T2 is always shorter than T2.
Imaging sequences can take advantage of these inherent parameters to produce T2-
weighted images. The NMR signal is usually read at a time interval known as the echo
time (TE) after the RF pulse has been applied. As TE increases, more dephasing can occur
due to T2 effects, leading to greater signal loss. For a given TE, the signal intensity of a
substance with a long T2 will be greater than that of a substance with a short T2 . These
differences are translated into image contrast.
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Figure 2-7: Loss of transverse magnetization due to differences in local magnetic
fields experienced by the protons.
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2.3 PULSE SEQUENCES
Different combinations of RF pulses can be used to produce different types of MR
signals and different types of images. The two most commonly used sequences are the
spin echo and the gradient echo.
2.3.1. Spin Echo
The spin echo pulse sequence consists of two RF pulses, 900 and 180%, separated
in time by an interval equal to TE/2 (figure 2-8). The signal is read at a time of TE. The
90' RF pulse will tip the net magnetization to the transverse plane. Because of T2 effects
the spins will lose phase coherence during the time TE/2. The 180" RF pulse is applied
along either the x or y direction. Its effect is to cause the spins to rotate 1800, but without
loss of precessional frequency. In the equivalent time TE/2, the protons will realign,
causing an "echo" in the signal measurement (figure 2-8). The 180' RF pulse has in effect,
rephased or refocused static inhomogeneities in the sample (such as the imperfections of the
external magnetic field). It is unable however to refocus dynamic or nonstatic
inhomogeneities inherent within the sample which are responsible for T2 . Therefore, spin
echo sequences are T2-weighted rather than T2 -weighted.
900 1800RF TE/2
S
Figure 2-8: A typical spin echo sequence. The 900 RF pulse is seperated from the
180* RF pulse by a time TE/2. An echo occur at a time TE.
2.3.2. Gradient Echo
The gradient echo pulse sequence consists of a 900 RF pulse and externally applied
linear magnetic field gradients. These gradients are applied between the RF pulse and the
signal read out which occurs at a time TE. The first gradient will dephase the spins and is
thus called a dephasing gradient. The second gradient is usually equal in magnitude but
reversed in sign. It rephases the spins and is therefore called a rephasing gradient. This
gradient reversal will cause a gradient echo to occur at the time TE. The absence of the
1800 refocus pulse generates images which are weighted by T2 rather than T2 . Gradient
echo images are therefore sensitive to the inhomogeneities in the externally applied
magnetic field, but also to static inhomogeneities present within the sample, such as large
iron deposits (such as sites of hemorrhage). These effects, known as magnetic
susceptibility effects will be discussed in the following sections.
2.4 MAGNETIC SUSCEPTIBILITY
Magnetic susceptibility is a substance's ability to attract or repel the lines of force of
an externally applied magnetic field. These effects are dominated by the electrons of a
sample, especially unpaired electrons which have both spin and orbital angular momentum.
2.4.1. Diamagnetism
Most organic and many inorganic compounds of low molecular weight which have
paired electrons are diamagnetic. Such materials weakly repel magnetic lines of force and
therefore reduce the local magnetic field. Although most tissues are diamagnetic, the signal
changes which occur due to this property are more typically overwhelmed by larger effects
of signal loss, such as relaxation. NMR imaging artifacts at air-tissue interfaces are
nonetheless due to this effect.
2.4.2. Paramagnetism
Many transition metal ions and lanthanide metals have unpaired orbital electrons,
with a spin of 1/2, which behave much like the hydrogen nucleus when exposed to an
external magnetic field. That is to say that they tend to align themselves parallel or anti-
parallel to the applied field. Since more align with the field than against it, the local
magnetic field surround this atom or molecule is enhanced. Such materials are known as
paramagnetic materials. The amount by which the local field is enhanced is proportional to
the strength of the applied magnetic field Bo:
M = XBo (2.2)
where the constant of proportionality, X, is called the magnetic susceptibility of the
material. Elements such as gadolinium and dysprosium are used as contrast agents in
NMR. A thorough review of paramagnetic metal complexes as contrast agents for MRI is
presented by Lauffer et al. (40). The effect of a contrast agent on the relaxation rates 1/T1,
1/T2 and 1/T2 can be divided into two groups. Changes in T1 occur because of a magnetic
field interaction between the electron magnetic dipole and the proton nuclear magnetic
dipole. The molecules in the contrast agent are also able to enhance the local magnetic
fields which increases the inhomogeneities seen by the protons in the environment. This
effect, known as susceptibility induced relaxation will shorten the T2 and T2*. In either
situation, the changes may be expressed as follows:
1 1
AR1= - I
Tlpost Tlpre
1 1AR2 = (2.3)
T2post T2pre
AR2* 1 1
post pre
One of the most common contrast agents used in clinical MRI is a gadolinium atom
chelated with diethylenetriaminepentaacetic acid (Gd-DTPA). Following intravenous
administration, this agent travels through the vasculature and diffuses into the extracellular
compartment, except in the brain because of the presence of an intact blood brain barrier.
The localization of the contrast agent within the vasculature of the brain induces a magnetic
susceptibility difference between the intravascular and extravascular spaces of 2.8 x 10-8
/mM Gd (41). This will shorten the tissue T2 such that a decrease in signal intensity in T2-
weighted images can be seen during the first pass of the contrast agent through the
vasculature (figure 2-9).
2.4.3. Superparamagnetism
Materials such as iron oxide are considered to be superparamagnetic because they
enhance the local magnetic field to an even greater extent than paramagnetic agents (42).
The field induced by these agents are also proportional to the applied external magnetic field
at low field strengths, but they saturate at high fields. A superparamagnetic agent known
as MION (Monocrystalline Iron Oxide Nanoparticle) was used in this study (34, 43). It is
composed of a core of iron oxide measuring approximately 4.5 nm in diameter, surrounded
by dextran molecules which gives the particle a total diameter of approximately 40 nm.
2.5 MR SUSCEPTIBILITY AND PULSE SEQUENCES
The compartmentalization of paramagnetic contrast agents within the vasculature or
cells induces long-range magnetic field perturbations that extend over many microns which
shorten the T2 and T2* of tissue. Assuming monoexponential decay, the enhancement of
the transverse magnetization relaxation rate caused by these agents and can be expressed as
follows:
AR2= 1 _1 1 n S post
T2 T2pre TE , So
(2.4)
AR2*= - -- In( postT2 T2 TE Spost pre o
where T2 pre and T2post are the tissue T2 in the absence and presence, respectively, of field
perturbations (similarly for T2*), So and Spost are the signal intensities in the absence and
presence of field perturbations, respectively.
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Figure 2-9: Dynamic cerebral passage of Gd-DTPA (0.2 mmol/kg). (a) Six SE
echo planar images (TR = 1 sec, TE = 100 msec) from the seris reflect the
parenchymal signal attenuation during transit of agent. (b) Time course from a
cortical region of interest.
The magnitude of AR2 and AR2* is dependent upon the diffusion of tissue protons
in the vicinity of susceptibility-induced field perturbations. Because spin echo sequences
use an 1800 RF pulse, they are capable of refocusing static inhomogeneities. However,
susceptibility differences combined with proton diffusion introduce nonstatic
inhomogeneities which are not completely refocused by spin echo sequences. As the echo
time is increased with respect to the diffusional correlation time, SE acquisitions become
more sensitive to magnetic susceptibility inhomogeneities. Gradient echo sequences on the
other hand are sensitive to static magnetic field inhomogeneities (like Bo imperfections) as
well as the effects of proton diffusion. Even in the absence of diffusion, considerable
signal attenuation will occur in the presence of susceptibility differences due to the range of
intravoxel Larmor frequencies induced.
The effects of proton diffusion in magnetic fields have been studied extensively
since Hahn's original work (44). In uniform gradients, Carr and Purcell derived an
expression for spin echo signal attenuation due to proton diffusion (45):
S = e -a 2/2 = e - 2G2T E 3D/12 (2.5)
where G is the gradient amplitude, g is the gyromagnetic ratio and D is the diffusion
coefficient. The effects of nonlinear gradients have also been studied by various
investigators (46-48). Glasel et. al. (49) investigated systems of heterogeneous water and
glass beads and concluded that the field gradients at the surface of small spheres can be
very large even if the susceptibility difference between the spheres and the surrounding
water is small. These results were later applied to physiological origins of susceptibility
variations, for example in transport and metabolism of cells (50), erythrocyte suspensions
(51, 52), and the oxygenation state of hemoglobin (53, 54).
The complete analysis of susceptibility-induced relaxivity must take into account the
diffusional rate of protons with respect to the size of the magnetic field perturbations.
Three regimes have been described which are determined by the magnetic, geometric and
dynamic properties of the system. These regimes, defined as the "motionally narrowed",
"intermediate" and "linear gradient" regimes are best defined in terms of the diffusive
correlation time of the protons with respect to the magnetic field inhomogeneities, tD, and
the characteristic variation in Larmor frequency due to field perturbations, 8o (55). For
localized magnetic field perturbers, TD is the time required for diffusion past the perturber,
and dw is the change in frequency on the surface of the perturber, expressed as (55):
TD r 2/D,
o• = yBeq(r),
where r is the radius of the perturber and Beq(r) is the magnetic field on the surface o the
perturber.
In the motionally narrowed regime, diffusion is fast compared to spatial variations
of field perturbations, such that tD8• << 1. This condition holds in regions where the size
of high-susceptibility is small, where water diffusion rates are high or where the frequency
shifts are small. In such a regime, Gillis and Koenig (56) found that the relaxation rate due
to a spherical perturber can be expressed as:
AR2 = 16tD f(50) 2/135 (2.7)
which varies quadratically with magnetic field and the radius of the perturber (r). In the
case of intravascular paramagnetic contrast agents, this would imply that for small vessels,
AR2 would vary as r2 .
At the opposite end of the spectrum, the linear gradient regime, ¶TD8 >> 1, holds
for cases of slow water diffusion or large field perturbations. In such a situation, the
variation of fields can be locally approximated by a linear gradient. Under these
conditions, Majumdar and Gore (29) showed that the transverse relaxation enhancement in
a spin echo experiment is well describe by:
AR2 = (yoGTE) 2 D/12 (2.8)
where o~ is the variance of the internal gradient distribution induced by the perturbation.
Weisskoff et. al. (31) used the modified Bloch equations with diffusion terms to produce
scaling rules which can be used for more general cases. Weisskoff noted that the diffusion
coefficient D should enter any relaxivity expression only the form D/r 2. As such, the
expression for AR2 in the linear gradient regime as derived by Majumdar and Gore (29) is
inversely proportional to the square of the radius of the perturber. Therefore, in the case of
intravascular paramagnetic contrast agents, the SE relaxitivity will approach zero as the size
of the vessels increases.
Gradient echo relaxivity on the other hand has been described by Brown (57, 58)
who derived an expression for AR2* induce by magnetite particles in the linear gradient
regime:
AR2* = (2t/3V-)f6c0 (2.9)
He concluded that in this regime, AR2* is independent of diffusion and by the same
argument as above, independent of perturber radius.
When TD8•O 1, the analytical approximations and solutions described above
cannot be applied to the intermediate regime. However, numerical techniques have been
applied to predict the response of both AR2 and AR2* (28, 31, 59-61). For example,
Monte Carlo simulations performed by Weisskoff et. al. (31) have estimated the enhanced
relaxivity of both SE and GE acquisitions in the presence of intravascular paramagnetic
contrast agents as a function of vessel size. Their results, shown in figure 2-10, not only
support the theoretical data described above, but also show the values of AR2 and AR2* in
the intermediate regime. Shown here for a concentration comparable to physiologic Gd-
DTPA injections, AR2 and AR2* first increase as a function of vessel size, corresponding
to the motionally narrowed regime. At larger vessel radii (> 8 pm), AR2 decreases to zero
whereas AR2* maintains a constant value, independent of vessel size. This corresponds to
the linear gradient regime. AR2 is seen to peak for vessels on the order of 3-4 pm,
corresponding to normal microvasculature, making SE pulse sequences more sensitive to
capillary blood volume.
Theoretical data courteously provided by Dr. Jerry Boxerman generated the plot
shown in figure 2-11 (see (32)). For a susceptibility difference of AX = 10-6 and a TE =
20 msec, the ratio of AR2* to AR2 was computed as a function of radius. These results
show an almost linear relationship between the ratio AR2*/AR2 and radius. This plot
supports the hypothesis that measurements of AR2 and AR2* and most importantly their
ratio could be used to obtain a index of the average vessel size within a voxel.
Based on this theory and the fact that tumor vessels can have diameters two to three
times greater than normal tissue capillaries (27), this research set out to obtain a regional
picture of tumor vascular morphology by measuring AR2 and AR2* as a function of
contrast agent concentration in a rat glioma model.
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Figure 2-10: Effect of vessel radius on AR2 and AR2* at AX = 10-6 and TE = 20
msec.
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Figure 2-11: AR2*/AR2 as a function of vessel radius for a AX = 10-6 and TE = 20
msec. This ratio could be used to obtain a index of the average vessel size within a voxel.
Chapter III
MATERIALS AND METHODS
The basic aim of these experiments was to measure the changes in the relaxation
rates (both 1/T2 and 1/ T2 ) as a function of contrast agent concentration and TE. Two sets
of experiments were performed. First, since susceptibility contrast mechanisms designed
to study the distribution of vessel sizes rely entirely on the compartmentalization of the
contrast agent within the vasculature, it is important to demonstrate that the disruption in the
blood brain barrier within the tumor does not cause the contrast agent to leak out of the
vasculature for the entire duration of the experiment. These experiments were performed
on two animals. Second, experiments were performed to measure AR2 and AR2* as a
function of contrast agent concentration and TE in four animals.
3.1 ANIMAL PREPARATION
Adult female Fisher 344 CD rats weighing 150-200g were used for this study.
Standard pelleted food and water ad libitum were given to the animals and a 12h light-dark
cycle was continuously maintained.
3.1.1 Day 1: Brain tumor implantation
Rats were anesthetized using 1% halothane. After immobilizing the heads in a
small rodent standard stereotactic apparatus (D. Kopf Instruments), the top of the heads
were treated with alcohol and a linear skin incision was placed over the midline. A 1 mm
burr hole was drilled in the skull approximately 3.5 mm lateral to the midline and 0.5 mm
behind the bregma on the left side. A Hamilton 10 iL gas-tight syringe (Hamilton-Comp.,
Reno, Nevada) was used for injection of 10 pL C6 glioma cell suspension (106 cells
cultured in DMEM) into the left frontal lobe at a depth of 3.5 mm relative to the dural
surface. The injection time was one minute, after which the needle was slowly retracted for
two minutes. Bone wax (Ethicon) was used to occlude the burr hole and to prevent leakage
of CSF. The skin was closed with stitches and the animals were allowed to recover from
the anesthesia under permanent observation. The entire procedure required approximately
fifteen minutes.
3.1.2 Day 2-19: Post-operative care
During the first three postoperative days, the rats were monitored twice daily for
incomplete wound closure, pain or distress. In case of pain, ibuprofen was given into the
drinking water at a dose of 400 mg/bottle.
Nineteen days after implantation of the tumor cells, the animals underwent the
imaging protocol described below. Rats were anesthetized with 1.5% halothane and the
femoral vein was catheterized for contrast agent administration. The animals were placed
supine on a water-heated pad and placed on the imaging table. Imaging took place on a 2T
1 lcm bore SISCO NMR image Spectrometer (Varian Associates, Fremont, CA) using a
custom built 40mm cosine volume coil.
3.2 IMAGING PROTOCOL
Conventional SE and GE images were acquired prior to and following each
injection of the equilibrium iron oxide contrast agent MION. For the spin echo sequence,
TR = 3000 msec was used and a series of echo times were obtained: TE = 20, 40, 60, 80
msec. Gradient echo sequences used a similar TR = 3000 msec but TE = 15, 20, 30, 40
msec. Both imaging sequences had the following parameters: FOV=3.5 x 3.5 cm, 64 x 64
resolution, slice thickness of 2 mm, and the number of slices ranged from three to five to
cover the entire tumor. Each image acquisition required 13 minutes. A post Gd-DTPA SE
image (TR=500 ms, TE-25 ms, 16 averages) was acquired to delineate the location of the
tumor. The animals were then sacrificed via carbon dioxide inhalation, the brain was
removed and fixed in OMNIFIX 2000 (Aaron Medical Industries Inc.) for at least 24
hours.
3.2.1. Equilibrium measurements
For this set of experiments, three injections of MION were given at a concentration
of 8 mg/mL. The imaging protocol described above was performed at the beginning of the
experiments and following each injection. After the last injection, the imaging protocol was
repeated three times, for a total of approximately 90 minutes.
3.2.2. AR2 and AR2* experiments
In these experiments, five serial injections of 5 mg/mL of MION were given,
preceded and followed by the imaging protocol described above.
3.3 IMMUNOHISTOCHEMISTRY
Immunohistochemical staining was performed in three tumors. Sections 2 mm
thick covering the location of the tumor were cut from the fixed brain and embedded in
paraffin (1 hr in 75% ethanol, lhr in 95 % ethanol, 4 x lhr in 100% ethanol, 2x 30 min in
xylene, 1 hr in melted paraffin at 57*C). Five micron slices were obtained through the
tumor and placed on standard histology slides. After one hour in a 60'C oven, the slides
were allowed to cool overnight.
To stain the slides, a standard immunohistochemical technique for laminin was used
to stain the vascular endothelial cells (62). The slides were deparaffanized by immersing
them for 2 x 10 min in xylene, followed by 3 min in 100% ethanol and 1 min each in 95%,
75% and 50% ethanol. The slides were then soaked in deionized water for 5 minutes
followed by 5 minutes in phospate buffered saline (PBS). Endogenous peroxidase activity
was blocked with methanol containing 0.3% H20 2 for 30 minutes. The slides were treated
with trypsin-EDTA (Gibco) for 1 min at 37"C and then immersed in cold PBS for 5 min.
Following a 20 minute incubation with 10% normal goat serum (Zymed Laboratories Inc.,
CA) tissue sections were incubated with the polyclonal anti-laminin antibody (Sigma, ) at
1:100 for 30 minutes. The slides were rinsed with PBS 2 x 5 min and incubated with
biotinylated secondary anti-rabbit IgG antibody (Zymed Laboratories Inc., CA) for 10
minutes. Following a PBS rinse (2 x 5 min), the slides were incubated with streptavidin
peroxidase conjugate solution for 5 minutes (Zymed Laboratories Inc., CA). Following a
PBS rinse, diaminobenzidine (DAB) was placed on the slides long enough for sufficient
staining to occur, as monitored under a microscope. Finally, the slides were counterstained
with hematoxalin (15 seconds), rinsed in tap water for 2 minutes and dehydrated using the
same alcohol baths as above, but in reverse order. Coverslips were placed on the slides
and allowed to dry overnight.
Morphometric analysis and quantification of microvascularization were performed
using BioQuand System IV morphometry software package (R&M Biometrics, Nashville,
TN) interface with an IBM microcomputer. Over 300 tumor vessels and over 200 grey
matter vessels were measured.
3.4 DATA ANALYSIS
From the MR images, a 4x4 pixel region of interest (ROI) was selected in the tumor
core and in the contralateral deep grey matter. The signal intensity averaged over these
ROIs was obtained at each point in the experiment (i.e. at baseline and following each
injection of contrast agent). The standard error of the ROI was used as an estimate of the
error. This may overestimate the error because the measurement includes the biological
variability inherent to the region of interest. AR2 and AR2* measurements were made for
each MION dose and each echo time according to equation (2.4). Standard error
propagation analysis was used to calculate the errors on AR2 and AR2*. Plots of AR2 and
AR2* as a function of dose and TE were made for each animal as well as a summary plot
of AR2 vs AR2* for all five animals.
Maps of AR2*/AR2 were produced on a pixel by pixel basis for one animals. At
each dose, both the SE and GE data as a function of TE were fit to a monoexponential
curve and interpolated to a value of TE = 20 ms. AR2, AR2* and their ratio (AR2*/AR2)
at TE = 20 ms were calculated at each dose and averaged to obtain a ratio map. In addition,
a total blood volume (CBV) map was obtained from the AR2* data (63, 64). Using the
same ROIs as described above, tumor blood volume was compared to grey matter blood
volume.
To validate the vessel size dependence of our AR2*/AR2 metric, we combined our
empirically measured distributions of vessel size in both normal grey matter and tumor
tissue with previous Monte Carlo simulation of the functional relation between AR2 and
AR2* and vessel size (32) to estimate a histologically realistic weighted average of
AR2*/AR2 ratio. The values of AR2* and AR2 from theoretical simulations performed at
TE = 20 ms and AX = 10-6 were weighted by the actual vessel sizes obtained from our
histologic data, as follows:
AR2 * _r 2 f(r)AGE(r) (3.1)AR2 I r2f(r)ASE(r)
where r is the radius of the vessel, f(r) is the number of vessels with radius r and AGE(r)
and ASE(r) are the amplitudes of the Monte Carlo determined values of AR2* and AR2 at
radius r, respectively. To obtain an error estimate on these calculations, random
distributions were generated from the measured vessel distributions. With each newly
generated distribution, the ratio AR2*/AR2 was computed according to Eq. [5] in both
tumor and grey matter. The quotient of these ratios (tumor/grey) was obtained and
compared with the measured MR ratio.
Chapter IV
RESULTS
Data from experiments described in chapter III will be presented in this chapter.
4.1 RAW DATA
Figure 4-1 shows a representative series of spin echo (TE = 60 msec) and gradient
echo (TE = 15 msec) images from one animal. Because gradient echoes decay with the
time constant T2 which is shorter than T2 , TE values for gradient echo images are shorter
than for spin echo images. These images show the decrease in signal intensity associated
with serial injections of the contrast agent MION. Because MION is an equilibrium agent,
it accumulates within the vasculature throughout the experiment, causing a cumulative
decrease in signal intensity with consecutive injections. In figure 4-1, the spin echo signal
intensity decreases by = 13% following each injection whereas the gradient echo signal
intensity decreases by - 17%.
4.2 EQUILIBRIUM EXPERIMENTS
To verify the stability of the contrast agent in the vasculature, steady state
measurements of AR2 and AR2* were performed as described. Figures 4-2 and 4-3 plot
AR2 and AR2* as a function of time for both the tumor and grey matter ROIs for two
animals at TE = 20 msec. The closed squares represent AR2 in the tumor core while the
open squares are measurements of AR2 in the contralateral deep grey matter. The closed
circles are measurements of AR2* in the tumor core and the open circles are measurements
of AR2* in the grey matter. Error bars are present on all data points, although some are too
small to appear on the graph. The first three points represent the measurements following
three consecutive injections of MION. Following the third injection, the imaging protocol
was repeated three times, for a duration of 90 minutes. For both tumor and grey matter,
the values of AR2 and AR2* remain constant, within errors, over 90 minutes. The values
of AR2 and AR2* within the tumor of the two animals did not change by more than 12%
over the course of the steady state measurements, indicating that the contrast agent is
remaining within the vasculature.
a) SE T2 images (TE = 60 msec)
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a) GE T2 images (TE = 15 msec)
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Figure 4-1: Spin and gradient echo images of a single slice following consecutive
injections of MION.
140
120
S100
& 80
60
40
20
0
ior GE
/ GE
y SE
or SE
0 50 100 150 200
Time (min)
Figure 4-2: AR2 and AR2* as a function of time for one animal (10-10-96) at TE = 20 msec.
Measurements of AR2* and AR2 remain constant, within errors, for 90 minutes.
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Figure 4-3: AR2 and AR2* as a function of time for one animal (04-30-97) at TE = 20
msec. Measurements of AR2* and AR2 remain constant, within errors, for 90 minutes.
4.3 AR2 AND AR2* EXPERIMENTS
There is also a difference in the ratio of AR2* to AR2 between the grey matter and
the tumor. For each dose and each stability point of figures 4-2 and 4-3, this ratio is
consistently larger in the tumor than in the contralateral deep grey. This trend was
reproduced in four animals who received five consecutive injections of MION. Figures 4-4
through 4-7 show plots of AR2 and AR2* as a function of contrast agent dose for each
animal at TE = 20 msec. As seen in all animals, the AR2* measurements were consistently
larger than the corresponding AR2 values, and both increase approximately linearly with
dose. As hypothesized, the ratio of AR2*/AR2 is greater for tumor than normal brain.
All measurements in these experiments were performed at various echo times. The
results from each animal at dose 3 are shown in figure 4-8 through 4-11. These are plots
of AR2 and AR2* as a function of TE. The AR2 measurements in each animal remain
quite independent of TE. The AR2* measurements in both tumor and grey matter show
different trends in each animal. Some decrease with increasing TE (figure 4-8) while
others increase with increasing TE (figure 4-9). The average of all four animals is shown
in figure 4-12. Within the standard deviation of the measurements, AR2 and AR2* for
both the tumor and the grey matter were independent of TE.
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Figure 4-4: AR2 and AR2* measurements for one animal (07-03-96) at TE = 20 msec as a function
of dose. The closed squares represent AR2 in the tumor, the open squares are AR2 measurements in
grey matter. The closed circles represent AR2* in the tumor and the open circles are AR2*
measurements in grey matter.
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Figure 4-5: AR2 and AR2* measurements for one animal (07-17-96) at TE = 20 msec as a function
of dose. The closed squares represent AR2 in the tumor, the open squares are AR2 measurements in
grey matter. The closed circles represent AR2* in the tumor and the open circles are AR2*
measurements in grey matter.
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Figure 4-6: AR2 and AR2* measurements for one animal (07-31-96) at TE = 20 msec as a
function of dose. The closed squares represent AR2 in the tumor, the open squares are AR2
measurements in grey matter. The closed circles represent AR2* in the tumor and the open circles are
AR2* measurements in grey matter.
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Figure 4-7: AR2 and AR2* measurements for one animal (08-07-96) at TE = 20 msec as a function
of dose. The closed squares represent AR2 in the tumor, the open squares are AR2 measurements in
grey matter. The closed circles represent AR2* in the tumor and the open circles are AR2*
measurements in grey matter.
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Figure 4-8: AR2 and AR2* measurements for one animal (07-03-96) at dose 3 as a function
of echo time. The closed squares represent AR2 in the tumor, the open squares are AR2
measurements in grey matter. The closed circles represent AR2* in the tumor and the open
circles are AR2* measurements in grey matter.
T)Ci
Cr
(4
Cr
60
50
40
30
20
10
0 · · · · · · · · I I I I I · · · · · · · I · · · · · · · · · · · · I · · i · · ·
Y-
30
25
20
15
10
10
Tumor GE
Grey GE
Grey SE
-- F "-Tumor SE
20 30 40 50 60 70 80 90
TE (msec)
Figure 4-9: AR2 and AR2* measurements for one animal (07-17-96) at dose 3 as a function of
echo time. The closed squares represent AR2 in the tumor, the open squares are AR2
measurements in grey matter. The closed circles represent AR2* in the tumor and the open circles
are AR2* measurements in grey matter.
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Figure 4-10: AR2 and AR2* measurements for one animal (07-31-96) at dose 3 as a function
of echo time. The closed squares represent AR2 in the tumor, the open squares are AR2
measurements in grey matter. The closed circles represent AR2* in the tumor and the open circles
are AR2* measurements in grey matter.
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Figure 4-11: AR2 and AR2* measurements for one animal (08-07-96) at dose 3 as a function
of echo time. The closed squares represent AR2 in the tumor, the open squares are AR2
measurements in grey matter. The closed circles represent AR2* in the tumor and the open
circles are AR2* measurements in grey matter.
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Figure 4-12: AR2 and AR2* measurements averaged over four animals at dose 3 as a
function of echo time. The closed squares represent AR2 in the tumor, the open squares are
AR2 measurements in grey matter. The closed circles represent AR2* in the tumor and the
open circles are AR2* measurements in grey matter.
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A summary of all four animals is shown in figure 4-13 which plots AR2* versus
AR2 for all doses at TE = 20 msec. The closed squares represent the data for the tumor
core while the open squares represent data from the contralateral deep grey. As seen on
this graph, the values of AR2* are greater than the values of AR2*. This difference can be
expressed quantitatively by taking the ratio of AR2* to AR2. By fitting the data to straight
lines through the origin, the following ratios were obtained:
AR2* * = 9.2 ± 1.0
AR2 tumor
AR2 * = 4.8 ± 03
AR2 grey
The ratio of these values was:
AR2 )tumor = 1.9 + 0.2
AR2 *
AR2 ) grey
From the histology sections, over 100 tumor vessel diameters in each of the three
tumors and over 200 grey matter vessel diameters were measured. The distribution of
vessels in the tumors and the grey matter are shown in figure 4-14. The average tumor
vessel diameter was 12.5 ± 6.8 pm and the average grey matter vessel diameter was 6.6 ±
2.1 pm. The predicted ratio of AR2*/AR2 computed using Eq. [5] and the MRI measured
ratio of AR2*/AR2 for tumor to grey matter are as follows
iAR2* 
= 6.6 ± 0.6
AR2 tumor
AR2 * = 3.6 ± 0.1
AR2 )grey
The relative ratio of these values was:CR2 )tum or = 1.9 + 0.1
AR2 *
AR2 )grey
Averaging over all four tumors, total tumor blood volume was 15% greater than the
blood volume in the contralateral grey matter. A GE CBV map for one animal is shown in
figure 7, along with a post-Gd T2 weighted SE image and a map of AR2*/AR2. In the
ratio map, an area of high intensity in the upper right region of the brain corresponds to the
location of the tumor as shown in the post-Gd image. Recalling that this ratio increases as
the average vessel increases (figure 2-11), this is suggestive of relatively larger
microvessels in the tumor than in the contralateral grey matter.
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Figure 4-13: AR2* versus AR2 for all four animals. The closed squares represent the tumor
and the open squares represent the contralateral grey matter.
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Figure 4-14: Distribution of vessels in tumor (a) and contralateral grey matter (b). The
average tumor vessel diameter was 12.5 ± 6.8 pm and the average grey matter vessel
diameter was 6.6 ± 2.1 plm.
21 0r
k\ ILVF·- · · I · · · · I ' -·-I ' ·- · I··-·_
0
Post-Gd GE CBV R2* / R2
Figure 4-15: Map of AR2*/AR2 for one animal (08-07-96). The post Gd T 1 SE image
on the left highlights the location of the tumor in the right hemisphere. The region of high
intensity in the corresponding location in the AR2*/AR2 map indicates that the tumor has a
greater density of larger microvessels than the contralateral hemisphere.
Chapter V
DISCUSSION
Although tumor angiogenesis is essential to the growth of all solid tumors, there
exists no direct or non-invasive method of assessing its role. Many studies have found via
invasive histological or three-dimensional casting techniques that tumor blood vessels are
associated with a wide range of both morphologic and physiologic characteristics not found
in normal capillaries (see e.g. (25-27, 65, 66)). Of particular interest to this study is the
fact that tumor capillary diameters can be two times greater than normal microvessels (65).
Magnetic susceptibility contrast mechanisms predict that larger microvessels will have a
greater ratio of AR2* to AR2 than normal smaller microvessels. For all animals in the
study, this ratio was indeed greater in the tumor than in the contralateral deep grey matter,
suggesting a higher relative density of larger vessels. On average, the measured tumor
ratio of AR2*/AR2 was a factor of 1.9 greater than the grey matter ratio, a value which was
in good agreement with that predicted by our own direct histologic assessment of vessel
size and previous susceptibility contrast modeling. From figure lb, the average vessel size
within the tumor and grey matter ROIs can be determined from the MRI and histologically
predicted values of AR2*/AR2. Although the absolute MRI values of AR2*/AR2 were
significantly larger than the predicted values resulting in larger estimates of vessel sizes, the
relative relationship between tumor and grey matter measurements are similar. This
difference in the absolute AR2*/AR2 values may be accounted for by a systematic bias in
our assessment of the true vascular distribution (potentially secondary to the paraffin
blocking process), or by differences between cylindrical and true vascular geometry in our
Monte Carlo simulations.
From the direct histology measurements, the relative size of the average tumor
vessel compared to the average grey matter vessel diameter was also 1.9 + 0.6. The good
agreement between the histologically determined ratio of vessel size between tumor and
grey matter and the AR2*/AR2 ratio between tumor and grey matter indicates that this
technique can be used to obtain a relative index of vessel size in areas of
pathophysiologically altered vascular proliferation.
Although the AR2 and AR2* measurements in this study were made at various echo
times, our results showed little TE dependence at the doses used. Boxerman et. al. (32)
showed that AR2 at AX = 3 x 10-8 decreased as a function of TE and the peak
susceptibility change also shifted towards smaller radii. This trend was not reproduced in
this study, perhaps due to the higher concentrations (hence AX's) studied. It is possible
that trends as a function of TE may have been masked by the interanimal variation,
especially in the exact values of AX with each injection. This variability could be more
properly addressed by obtaining quantitative AX measures on blood samples following
each injection. Should such differences as a function of TE ultimately be observed, these
may allow not only the mean vessel diameter within a voxel to be determined, but may also
provide enough information to calculate the distribution of vessels.
While previous MR studies have shown a correlation between increased blood
volume in tumors and tumor grade (23, 24, 67), none have addressed the question of
vessel size. A recent study by van Dijke et. al. (67) which measured the plasma volume in
a mammary carcinoma model using contrast-enhanced MR imaging techniques, showed a
positive correlation between histologically determined capillary number density and MR
measurements of plasma volume. Their relationship was not linear however. With
increasing tumor aggressiveness, an exponential rise in plasma volume was detected. They
suggested therefore that a simultaneous increase in size of vessels must accompany the
increase in vessel number. This is in agreement with our direct measurements of increased
vessel size at a late phase of tumor growth. It is of interest to note that the relative CBV of
the C6 gliomas calculated here was elevated by only about 15% compared to contralateral
grey matter compared, to a 90% increase in average vessel size. This suggests that an
increase in relative vessel size may provide unique, independent information on tumor
vessel physiology which complements relative CBV maps.
Tumor angiogenesis is a complex process which can be triggered by various factors
including stress and hypoxia (19, 68, 69). As such, angiogenic activity can be
heterogeneous throughout the tumor (15, 70), making it important to sample as much of the
tumor as possible. Although histologic data obtained from biopsy is the gold standard for
examining vascular morphology, it is subject to sampling errors because only one or two
portions of a tumor are probed during routine biopsy. In our C6 rat glioma model, it was
possible to examine much of the tumor on a pixel by pixel basis as shown in figure 5 (map
of AR2*/AR2). With multi-slice techniques, the entire volume of the tumor can be assayed
as opposed to small regions obtained with histologic techniques. Equally important, this
MR technique is non-invasive and can therefore be repeated over time.
Our results in these 19 day old tumors show a relatively homogeneous ratio of
AR2*/AR2 throughout. Further longitudinal studies should reveal a more complex pattern,
allowing us to examine the dynamics of vessel size evolution during tumor growth. Deane
and Lantos (25) found that vessels in a rat glioma model varied as the tumor progressed:
during the early phase, small vessels were found throughout the tumor; at late phases,
small vessels were only found at the proliferating edge of the tumor and larger microvessels
were found between the edge and the necrotic core. The tumors in this study were
examined only at one specific time point. Since the size of vessels within a tumor are
known to vary with the aggressiveness of the tumor (66), it may further be possible to find
a correlation between tumor grade and vessel size for various human tumors. Future
studies using methods similar to the one described here could be used to longitudinally
assess the fate of tumor blood vessels as a function of time and tumor size. This technique
may therefore not only help diagnose the stage and grade of tumors, but it may ultimately
be useful in assessing the response of tumors to therapy directed at the angiogenic process
(18, 71).
The conclusions drawn from these data may be limited in various ways. Several
studies have shown that the perfusion efficiency of brain tumors is significantly lower than
normal cortex (72-74). For example, Yuan et. al. (73) found that red blood cell velocity in
pial vessels may be an order of magnitude faster than that in tumor vessels of the same
diameter. Low flow could affect the MR measurements of AR2* and AR2 which rely on
the homogeneous distribution of the contrast agent. However, by using a long lived
intravascular agent and a prolonged imaging protocol (= 13 minutes), all perfused vessels
within the tumor should be adequately filled with contrast agent during the experiment since
even with flow rates an order of magnitude lower than those found in normal tissue,
vascular transit times are still less than one minute. Furthermore, modeling studies show
only a weak dependence of susceptibility contrast itself as a function of perfusion (32). We
therefore think it unlikely that low tumor perfusion significantly perturbs our
measurements.
Results from the C6 rat glioma model may also not be directly applicable to human
brain tumors or other tumors in general. Low grade tumors which have been known not to
be associated with as dramatic an increase in blood volume as high grade (23) may not
exhibit the corresponding increase in vessel diameter. Correlations between MR imaging
and histologic characteristics will differ with tumor type and level of angiogenic activity.
Furthermore, equilibrium blood pool contrast agents have yet to be approved for human
use. If this technique were to be applicable to humans today, similar data could be obtained
from first pass dynamic contrast agents such as Gd-DTPA. Unfortunately, these agents are
small enough to leak out of some disrupted tumor vasculature in high grade human brain
tumors, and normal vasculature outside the brain. In a tumor whose endothelial
permeability is greatly increased, Gd-DTPA may thus not be able to provide adequate
susceptibility-induced signal loss for measurement of AR2 or AR2*. Techniques relying
on first pass dynamic measurements of AR2* and AR2 would also be subjected to regional
variations in tumor perfusion. The low perfusion efficiency reported in tumors (72-74)
may therefore prevent the assessment of average vessel size via methods described in this
study due to the lack of signal attenuation. However, the assessment of tumor perfusion
efficiency itself may provide interesting information concerning the regional hemodynamics
present in tumors.
Despite these limitations, the technique described in this study shows that tumor
vessel sizes can be compared between normal and diseased tissue by injecting an
equilibrium blood pool contrast agent. With the advent of human approved intravascular
agents, magnetic susceptibility contrast mechanisms, which have already been useful in
determining relative cerebral blood volumes, may serve to provide further information
about human tumor vasculature and their response to therapy. This technique may be of
particular interest in studying, non-invasively, the effects of novel anti-angiogenic drugs on
the existing tumor vasculature.
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